Every 8-K that American Well Corporation (AMWL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMWL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMWL filings page.
American Well Corporation reported Q2 2026 revenue of $52.0 million, at the top of its guidance range but below $70,898 thousand a year earlier. Subscription revenue was $25.7 million and Amwell Medical Group visit revenue $24.4 million, with 0.8 million total visits. Gross margin was 53%. Net loss was ($9.6) million, improving from $10.3 million in Q1 2026, and adjusted EBITDA narrowed to a ($1.2) million loss from $3.1 million.
The company noted operating cash inflows in the first half of 2026 and highlighted having no debt. For 2026, Amwell now guides revenue to $200–$205 million, up from $195–$205 million, and expects adjusted EBITDA of a ($9)–($7) million loss, improved from a ($16)–($12) million loss range. Q3 2026 guidance calls for revenue of $46–$48 million and adjusted EBITDA of a ($5)–($3) million loss, while reiterating an objective of positive cash flow from operations in Q4 2026.
American Well Corporation changed its external auditor. On July 14, 2026, the Audit Committee dismissed PricewaterhouseCoopers LLP as the independent registered public accounting firm and appointed BDO USA, P.C. as the new independent registered public accounting firm.
American Well states that PwC’s audit reports on the company’s financial statements for the fiscal years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications and that there were no disagreements or reportable events under Item 304(a) of Regulation S‑K during those periods and through July 14, 2026. PwC has been asked to provide a letter to the SEC regarding these disclosures, filed as Exhibit 16.1 and dated July 20, 2026.
American Well Corporation reappointed Stephen Schlegel as a Class III director on July 11, 2026, for a term expiring at the company’s 2029 annual meeting of stockholders. Shortly before this, on July 8, 2026, he resigned as a Class II director.
The company states that his resignation and reappointment were undertaken solely to rebalance the three director classes so they are approximately equal in size, as required by NYSE listing standards, and not due to any disagreement over operations, policies, or practices. His committee assignments and compensation arrangements remain unchanged, with further background information referenced in the definitive proxy statement on Schedule 14A filed on April 24, 2026.
American Well Corporation held its 2026 annual meeting of stockholders on June 16, 2026. Stockholders elected Class III director Dr. Ido Schoenberg, who received 20,509,462 votes for and 954,941 withheld, with 2,507,946 broker non-votes, to serve until the 2029 annual meeting.
Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 23,945,239 votes for and 27,110 withheld. In a non-binding advisory vote, stockholders approved the named executive officer compensation, with 21,137,741 votes for, 326,662 withheld, and 2,507,946 broker non-votes.
American Well Corporation reports that co-founder Dr. Roy Schoenberg has resigned from its Board of Directors, effective May 6, 2026. The company explains that he is leaving in connection with a new employment opportunity.
His resignation is described as not resulting from any disagreement with American Well on operations, policies, or procedures. The company highlights his nearly twenty years of leadership, including service as Executive Vice Chairman of the Board, and credits him with a lasting impact on its growth and evolution.
American Well Corporation reported first quarter 2026 results with shrinking losses but lower revenue year over year. Revenue was $54.9 million, down from $66.8 million a year earlier, with a gross margin of 51%.
Net loss was $10.3 million, improving from $18.4 million in first quarter 2025 and $25.2 million in fourth quarter 2025. Adjusted EBITDA was a loss of $3.1 million, better than a $12.2 million loss a year ago and $10.3 million in fourth quarter 2025. Total visits reached 1.1 million.
For full year 2026, Amwell reaffirmed revenue guidance of $195–$205 million, AMG visits of 1.32–1.37 million, and updated adjusted EBITDA guidance to a loss of $16–$12 million. For second quarter 2026, it expects revenue of $48–$52 million and adjusted EBITDA of a $4–$2 million loss, and continues to target positive cash flow from operations in the fourth quarter of 2026.
American Well Corporation reports that board member Dr. Peter Slavin has notified the company he will resign from its Board of Directors, effective at the company’s next annual meeting of stockholders in 2026. He will continue to serve as a director until that meeting.
The company states that Dr. Slavin’s decision is due to his transition to a new role on the West Coast of the United States and is not the result of any disagreement regarding American Well’s operations, policies, or procedures. The company expresses appreciation for his more than nine years of board service.
American Well Corporation reported fourth-quarter and full-year 2025 results showing sharply reduced losses and improving efficiency. Q4 2025 revenue was $55.3 million with a 51% gross margin, and net loss narrowed to $25.2 million, compared with $31.9 million in the third quarter. Adjusted EBITDA improved to $(10.3) million from $(12.7) million in the prior quarter, with total visits of 1.0 million.
For full-year 2025, revenue was $249.3 million, gross margin was 53%, and net loss declined to $95.0 million from $212.6 million in 2024. Adjusted EBITDA improved to $(39.9) million from $(134.4) million, on 4.5 million total visits, and year-end cash and short-term securities were about $182.3 million.
For 2026, Amwell guides revenue to $195–$205 million, AMG visits to 1.32–1.37 million, and adjusted EBITDA to $(24)–$(18) million, with Q1 2026 revenue of $48–$53 million and adjusted EBITDA of $(7)–$(5) million. Management also targets positive cash flow from operations in the fourth quarter of 2026.
American Well Corporation reported that it entered into an Amended and Restated Statement of Work with Elevance Health, Inc., effective January 1, 2026. This agreement extends their partnership under which American Well operates the white‑labelled LiveHealth Online® digital care delivery platform for Elevance Health. Elevance Health is obligated to pay American Well annual subscription fees and can separately engage the company for professional services, development, innovation, and engagement marketing work.
The new Statement of Work has a three‑year term, running from January 1, 2026 through January 1, 2029, and will automatically renew for additional one‑year periods unless either party terminates it. Either party may terminate for specified breaches or insolvency, and Elevance Health also has the right to terminate for certain security or confidentiality breaches, change‑of‑control events, or for convenience with 365 days’ advance written notice.
American Well Corporation disclosed that it has extended its long-standing partnership with Elevance Health, Inc. for digital care services. On December 24 and 25, 2025, the company amended its Master Services Agreement and entered into a new Healthy Impact Statement of Work, effective January 1, 2026, to continue operating the white‑labelled LiveHealth Online® digital care platform. Under these agreements, Elevance Health pays annual subscription fees and can engage American Well for additional professional, development, innovation, and engagement marketing services.
Both the Master Services Agreement and the Healthy Impact Statement of Work now run for 3 years from January 1, 2026 through January 1, 2029, with automatic one‑year renewals unless terminated. Elevance Health has various termination rights, including for convenience with 365 days’ notice. American Well’s clinical partner, Online Care Group, PC, also extended related provider agreements for the same 3‑year term, ensuring continued prioritized access to a 50‑state network of clinicians who deliver digital care consultations to Elevance Health members via LiveHealth Online.
American Well Corporation (Amwell) reported that it announced financial results for the fiscal quarter ended September 30, 2025. The company furnished its Earnings Report as Exhibit 99.1.
Amwell will host a conference call to discuss results today at 5 p.m. ET, accessible via live webcast at the provided link. A replay will be available for approximately 90 days at investors.amwell.com. The furnished materials are not deemed “filed” under Section 18 of the Exchange Act.